New, robust methodology is side benefit
HUNTSVILLE, Ala. --Whether or not a gene is expressed, that is, whether it is turned on or turned off, is in part controlled by a group of proteins called transcription factors. Scientists in the Myers lab at the HudsonAlpha Institute recently published results of a basic research project undertaken to better understand mechanisms that determine cell type-specific transcription factor binding.
Study of the epigenome searches for disease triggers
Using genome-wide analyses, researchers at the HudsonAlpha Institute for Biotechnology along with clinical and research partners at the University of Alabama at Birmingham, have released the largest published study that examines epigenetic risk pathways for lupus. Lupus is an autoimmune disease that occurs primarily in women and is known to have both genetic and epigenetic causes. The disease may affect various parts of the body, especially the skin, joints, blood and kidneys.
HudsonAlpha and UAB researchers work to identify optimal treatments for the most common form of breast cancer
Komen funds collaborative effort using tumor genomics to identify effective treatments
HUNTSVILLE, Ala. – The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.
NIH study seeks genetic links to answer the “Why?” of unexplained disorders
HUNTSVILLE, Ala -- Even in the absence of a ready solution, knowing why a child faces physical, emotional and intellectual challenges is helpful to physicians and families. Researchers at the HudsonAlpha Institute for Biotechnology are using high throughput genomic sequencing to meet major diagnostic needs for childhood genetic disorders through a multi-year grant potentially totaling more than $7.6 million from the National Institutes of Health.